| ［1］ |
Siegel RL，Miller KD，Fuchs HE，et al. Cancer statistics，2022［J］. CA Cancer J Clin，2022，72（1）: 7-33.
|
| ［2］ |
Gandaglia G，Leni R，Bray F，et al. Epidemiology and prevention of prostate cancer［J］. Eur Urol Oncol，2021，4（6）: 877-892.
|
| ［3］ |
冉标，王普泽，杨嘉豪，等. 转移性前列腺癌的精准治疗前沿进展［J］. 西部医学，2024，36（6）: 931-936.Ran B，Wang PZ，Yang JH，et al.Research progress in precision medicine of metastatie prostate cancer［J］.Med J West China，2024，36（6）: 931-936.
|
| ［4］ |
吴洪瀚，范青洪，瓦庆德. 前列腺癌骨转移治疗研究进展［J］. 遵义医科大学学报，2024，47（4）: 424-431.Wu HH，Fan QH，Wa QD.Progress in bone metastases treatment for prostate cancer［J］. J Zunyi Med Univ，2024，47（4）: 424-431.
|
| ［5］ |
丁婷婷，郝珊瑚，王治国，等. 18F-PSMA-1007 PET/CT与18F-FDG PET/CT对前列腺癌骨转移的诊断价值比较［J］. 江苏大学学报（医学版），2023，33（5）: 369-373，379.Ding TT，Hao SH，Wang ZG，et al. Diagnostic value of 18F-prostatespecific membrane antigen-1007 PET/CT versus 18F-deoxyglucose PET/CT for bone metastasis in prostate cancer［J］. J Jiangsu Univ Med Ed，2023，33（5）: 369-373，379.
|
| ［6］ |
杨恺惟，虞巍，宋毅. 多西他赛联合卡铂治疗转移性去势抵抗性前列腺癌的临床探索［J/OL］. 中华临床医师杂志（电子版），2023，17（1）: 23-27.Yang KW，Yu W，Song Y. Effectiveness of docetaxel in combination with carboplatin in patients with metastatic castration resistant prostate cancer［J/OL］. Chin J Clinicians（Electronic Edition），2023，17（1）: 23-27.
|
| ［7］ |
陈钊，钟克力，江志鹏，等. 前列腺癌术后腹股沟疝的发生率及危险因素分析［J］. 中华疝和腹壁外科杂志（电子版），2024，18（4）:396-401.Chen Z，Zhong KL，Jiang ZP，et al. Analysis of incidence and risk factors of inguinal hernia after prostate cancer surgery［J］. Chin J Hernia Abdom Wall Surg （Electronic Edition），2024，18（4）: 396-401
|
| ［8］ |
黄威，付伟金，张明津，等. 帕博利珠单抗治疗去势抵抗性前列腺癌的研究进展［J］. 实用医学杂志，2023，39（11）: 1376-1381.Huang W，Fu WJ，Zhang M，et al. Research progress of pembrolizumab in the treatment of castration -resistant prostate cancer［J］. J Pract Med，2023，39（11）: 1376-1381.
|
| ［9］ |
Sharma BK，Kakker NK，Bhadouriya S，et al. Effect of TLR agonist on infections bronchitis virus replication and cytokine expression in embryonated chicken eggs［J］. Mol Immunol，2020，120: 52-60.
|
| ［10］ |
Ichinohe T. Respective roles of TLR，RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design［J］. Expert Rev Vaccines，2010，9（11）: 1315-1324.
|
| ［11］ |
Rudin CM，Poirier JT，Senzer NN，et al. Phase I clinical study of Seneca Valley Virus （SVV-001），a replication-competent picornavirus，in advanced solid tumors with neuroendocrine features［J］. Clin Cancer Res，2011，17（4）: 888-895.
|
| ［12］ |
Lichty BD，Breitbach CJ，Stojdl DF，et al. Going viral with cancer immunotherapy［J］. Nat Rev Cancer，2014，14（8）: 559-567.
|
| ［13］ |
Chesney J，Puzanov I，Collichio F，et al. Randomized，open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced，unresectable melanoma［J］. J Clin Oncol，2018，36（17）: 1658-1667.
|
| ［14］ |
Cai J，Yan G. The identification and development of a novel oncolytic virus: alphavirus M1［J］. Hum Gene Ther，2021，32（3/4）: 138-149.
|
| ［15］ |
许青，陆舜，朱蕙燕，等. 溶瘤病毒治疗恶性肿瘤临床应用上海专家共识（2021年版）［J］. 中国癌症杂志，2021，31（3）: 231-239.Xu Q，Lu S，Zhu HY，et al. Shanghai expert consensus on clinical application of oncolytic virus in the treatment of malignant tumors（2021 edition）［J］. China Oncol，2021，31（3）: 231-239.
|
| ［16］ |
Zhang H，Lin Y，Li K，et al. Naturally existing oncolytic virus M1 is nonpathogenic for the nonhuman Primates after multiple rounds of repeated intravenous injections［J］. Hum Gene Ther，2016，27（9）:700-711.
|
| ［17］ |
赵华新，王雪珂，许青. 前列腺癌溶瘤病毒治疗研究进展［J］. 医学综述，2020，26（9）: 1735-1739，1745.Zhao HX，Wang XK，Xu Q. Progress in oncolytic virus therapy for prostate cancer［J］. Med Recapitulate，2020，26（9）: 1735-1739，1745.
|
| ［18］ |
Hu C，Liu Y，Lin Y，et al. Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer［J］. Cell Death Dis，2018，9（3）: 274.
|
| ［19］ |
Lin Y，Zhang H，Liang J，et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers［J］. Proc Natl Acad Sci U S A，2014，111（42）:E4504-E4512.
|
| ［20］ |
肖晓，周雅思，彭楚茵，等.溶瘤病毒M1诱导宫颈癌细胞C-33A凋亡的作用及机制.中国药房，2021，32（23）: 2827-2831.Xiao X，Zhou YS，Peng CY，et al.Effects and mechanism of oncolytic virus Ml inducing the apoptosis of cervical cancer C-33A cells［J］.China Pharmacy，2021，32（23）:2827-2831.
|
| ［21］ |
卞京，朱美玲，李夏伊，等.溶瘤病毒在胃癌治疗中的研究进展［J］.肿瘤，2020，40（3）: 223-232.Bian J，Zhu ML，Li XY，et al. Progress of oncolytic virus in treatment of gastric cancer［J］. Tumor，2020，40（3）: 223-232.
|
| ［22］ |
Sun S，Liu Y，He C，et al. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer［J］. Cancer Lett，2021，502: 9-24.
|
| ［23］ |
Wang G，Liu Y，Liu S，et al. Oncolyic virotherapy for prostate cancer:lighting a fire in winter［J］. Int J Mol Sci，2022；23（20）:12647.
|
| ［24］ |
Graff JN，Alumkal JJ，Drake CG，et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer［J］. Oncotarget，2016，7（33）: 52810-52817.
|
| ［25］ |
Le DT，Durham JN，Smith KN，et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade［J］. Science，2017，357（6349）: 409-413.
|
| ［26］ |
Hansen AR，Massard C，Ott PA，et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study［J］.Ann Oncol，2018，29（8）: 1807-1813.
|
| ［27］ |
Ping F，Wang Y，Shen X，et al. Virtual screening and molecular docking to study the mechanism of Chinese medicines in the treatment of coronavirus infection［J］. Med Sci Monit，2022，28: e934102.
|
| ［28］ |
You J，Li H，Fan P，et al. Inspiration for COVID-19 treatment:network analysis and experimental validation of baicalin for cytokine storm［J］. Front Pharmacol，2022，13: 853496.
|
| ［29］ |
Cheng Y，Sun F，Wang L，et al. Virus-induced p38 MAPK activation facilitates viral infection［J］. Theranostics，2020，10（26）: 12223-12240.
|